CP-91149

Research use only, not for human use.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.

CP-91149 treatment decreases muscle GP activity by converting the phosphorylated AMP-independent α form into the dephosphorylated AMP-dependent b form and inhibiting GP α activity and AMP-mediated GP b activation. CP-91149 (10, 30, 50 μM) inhibits brain GP and causes glycogen accumulation in A549 cells. Cell Viability AssayCell Line:Cells were transduced with adenoviruses and incubated in the presence of 25 mM glucose for 2 days. Concentration:10 μM (glucose? or glucose+ for 18 h).Incubation Time:3 h.Result:Promoted the conversion of GP a into GP b, according to α model proposed in hepatocytes.Western Blot Analysis Cell Line:A549 cells. Concentration: 0, 10, 30, 50 μM.Incubation Time:72 h.Result:A significant increase in glycogen accumulation was detected at 10 μM of CP-91149 as compared with untreated cells with a maximal glycogen accumulation at 30 μM. Intracellular glycogen content decreased at 50 μM CP-91149, perhaps explained by additional pharmacological effects of the drug. The dose-dependent accumulation of intracellular glycogen in A549 cells by CP-91149 indicates that CP-91149 inhibits brain GP in tissue culture.

——

CP-91149 | CP 91149 | CP91149

Membrane Transporter/Ion Channel

OCT

Glycogen phosphorylase (GP)

Metabolic Disease

——

186392-40-5

399.87

C21H22ClN3O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (250.08 mM)

CN(C)C(=O)[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CC2=CC(Cl)=CC=C2N1

1H-Indole-2-carboxamide, 5-chloro-N-((1S,2R)-3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl)-

(-20℃)

With Ice Pack

≥ 2 years